Perioperative Chemo and Pembrolizumab in Gastric Cancer

Summary

This is a non-randomized, multi-site, open-label trial of pembrolizumab and chemotherapy in subjects with gastric or gastroesophageal (GE) junction adenocarcinoma. The purpose of this study is to determine and evaluate the efficacy of combination therapy with immune checkpoint blockade and chemotherapy used in the perioperative period in eradicating micrometastatic disease; and to compare paired tissue and serum samples (pre-treatment and post-treatment) from individually treated patients to explore the immune effects of combination therapy and predictors of response.

Timeline

Start

2017-11-25

Primary completion

2023-02-28

Completion

2023-02-28

Outcome

Met primary endpoint

paper This trial met its primary end point PMID 37856106 ↗

Publications

• Manji GA, Lee S, Del Portillo A, May M, Ana SS, Alouani E, Sender N, Negri T, Gautier K, Ge L, Fan W, Xie M, Sethi A, Schrope B, Tan AC, Park H, Oberstein PE, Shah MA, Raufi AG. Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma. JAMA Oncol. 2023 Dec 1;9(12):1702-1707. doi: 10.1001/jamaoncol.2023.4423.

Drugs

Indications